Core-corona procedure and microcanonical hadronization to understand strangeness enhancement in proton-proton and heavy ion collisions in the EPOS4 framework
Physical Review C · 26.01.2024 · 109 (1)
DOI: 10.1103/physrevc.109.014910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physical Review C, online erschienen am 26.01.2024. Verfasst von K. Werner. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The multiplicity dependence of multistrange hadron yields in proton-proton and lead-lead collisions at several TeV allows one to study the transition from very big to very small systems, in particular, concerning collective effects. I investigate this, employing a core-corona approach based on new microcanonical hadronization procedures in the 4 framework, as well as new methods allowing one to transform energy-momentum flow through freeze-out surfaces into invariant-mass elements. I try to disentangle effects due to “canonical suppression” and “core-corona separation”, which will both lead to a reduction of the yields at low multiplicity. Published by the American Physical Society 2024
Zitieren
APA
Werner, K. (2024). Core-corona procedure and microcanonical hadronization to understand strangeness enhancement in proton-proton and heavy ion collisions in the EPOS4 framework. Physical Review C, 109(1). https://doi.org/10.1103/physrevc.109.014910
Vancouver
Werner K. Core-corona procedure and microcanonical hadronization to understand strangeness enhancement in proton-proton and heavy ion collisions in the EPOS4 framework. Physical Review C. 2024;109(1). doi:10.1103/physrevc.109.014910
BibTeX
@article{Werner2024,
author = {Werner, K.},
title = {Core-corona procedure and microcanonical hadronization to understand strangeness enhancement in proton-proton and heavy ion collisions in the EPOS4 framework},
journal = {Physical Review C},
year = {2024},
volume = {109},
number = {1},
doi = {10.1103/physrevc.109.014910}
}
EUVIMED